Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension
SJ Pittock, K Fujihara, J Palace… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Multiple Sclerosis Journal, 2022•journals.sagepub.com
During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event
study) and its open-label extension (interim analysis), 33 adults with aquaporin-4
immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD)
received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At
192 weeks (~ 4 years), 96% of these patients were free from adjudicated relapses (Kaplan–
Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95%(20/21) of …
study) and its open-label extension (interim analysis), 33 adults with aquaporin-4
immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD)
received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At
192 weeks (~ 4 years), 96% of these patients were free from adjudicated relapses (Kaplan–
Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95%(20/21) of …
During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan–Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.
Sage Journals